Last edition
News about "pannexin 1 "
PannTheraPi Gets French Approval to Advance PTI5803 into Phase 2a Epilepsy Trial
PannTheraPi will evaluate PTI5803 across three dose levels, focusing on safety, tolerability and preliminary efficacy in patients with drug-resistant focal cortical dysplasia-associated epilepsy.
Pannexin 1 | 09/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members